~~<i id='348087FA2B'><strike id='348087FA2B'><tt id='348087FA2B'><pre id='348087FA2B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：comprehensive 2025-09-02 22:08:20 - browse：43

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The strange history of BMI, the body mass index

explore

focus

entertainment

hotspot

Wikipedia

focus

WhogetstosuetheFDA?Ispharmacaughtinatradewar?Andwhatdoes“AF”standfor?Wecoverallthatandmorethisweekon

WSS

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Readout LOUD podcast: mifepristone case, GLP

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Why do we get seasonal allergies?

Abortion pill case raises question: who can sue the FDA?

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

hotspot

comprehensive

explore

Bright Health sells Medicare Advantage business to Molina

Primary care physicians play key roles in Alzheimer's management

Drug repurposing or repositioning? The language matters

Will generative AI in health care meet the fate of IBM's Dr. Watson?

DIEP, the 'gold standard' of breast reconstruction, is under threat

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Psychedelics group wrestles with new pharma identity

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

23andMe had bad news about my health. I wish a person had delivered it

Will generative AI in health care meet the fate of IBM's Dr. Watson?

focus

Merck drug for rare lung condition set for approval in U.S.

Primary care physicians play key roles in Alzheimer's management

Illumina to lay off 10% of research and development team

Tuskegee Airman Raymond Cassagnol dies at 102

Washington mulls new rules to avert another Change Healthcare

Why do we get seasonal allergies?

entertainment

hotspot

Wikipedia

focus